Literature DB >> 19403182

Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease.

Takahiro Sawada1, Junya Shite, Toshiro Shinke, Hiromasa Otake, Yusuke Tanino, Daisuke Ogasawara, Hiroyuki Kawamori, Hiroki Kato, Naoki Miyoshi, Naoki Yoshino, Amane Kozuki, Ken-ichi Hirata.   

Abstract

BACKGROUND: Previous studies demonstrated the inverse association of adiponectin with coronary artery disease (CAD) especially in men with acute coronary syndrome, however their association with in vivo plaque vulnerability in stable CAD, which may be reflected by the thin-cap fibroatheroma (TCFA) prevalence, remains unknown.
METHODS: In 50 men with stable CAD, we identified TCFA with multi-vessel examination of combined use of virtual histology intravascular ultrasound (VH-IVUS) and optical coherence tomography (OCT). The definition of TCFA was described as follows; necrotic-core rich lesion (% necrotic-core >10%) without evidence of an overlying fibrous component and % plaque-volume >40% in at least 3 consecutive frames by VH-IVUS, and the thinnest fibrous-cap thickness <65 microm by OCT. The patients were divided into two groups, patients with TCFA and without TCFA, and plasma adiponectin level was compared between the groups.
RESULTS: Among 50 patients, we could observe 116 vessels (2.32+/-0.47 vessel/patient). At least one TCFA was identified in 20 patients. Patients with TCFA had significantly lower plasma adiponectin levels than patients without TCFA (P<0.0001). Furthermore, the plasma adiponectin levels in patients with multi-vessel TCFA were significantly lower than those in patients with single-vessel TCFA (P=0.049). Multivariate logistic regression analysis revealed that plasma adiponectin was the strongest predictive factor of the presence of TCFA (P=0.0007).
CONCLUSIONS: Low plasma adiponectin was associated with the presence of TCFA in men with stable CAD. This finding suggests that, in these subjects, it may be a biomarker that can be used to stratify "vulnerable patients" into risk categories. Copyright (c) 2009. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403182     DOI: 10.1016/j.ijcard.2008.12.216

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

1.  Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.

Authors:  Brian A Bergmark; Christopher P Cannon; William B White; Petr Jarolim; Yuyin Liu; Marc P Bonaca; Faiez Zannad; David A Morrow
Journal:  Diabetes Obes Metab       Date:  2017-03-17       Impact factor: 6.577

Review 2.  The Role of Adipocytokines in Coronary Atherosclerosis.

Authors:  Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Matteo Casula; Franco Dallegri; Fabrizio Montecucco; Federico Carbone
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

3.  Diagnosis of Thin-Capped Fibroatheromas in Intravascular Optical Coherence Tomography Images: Effects of Light Scattering.

Authors:  Jennifer E Phipps; Taylor Hoyt; Deborah Vela; Tianyi Wang; Joel E Michalek; L Maximilian Buja; Ik-Kyung Jang; Thomas E Milner; Marc D Feldman
Journal:  Circ Cardiovasc Interv       Date:  2016-07       Impact factor: 6.546

Review 4.  The evolving role of adiponectin as an additive biomarker in HFrEF.

Authors:  Tahnee Sente; Andreas Gevaert; An Van Berendoncks; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

5.  Perivascular adipose adiponectin correlates with symptom status of patients undergoing carotid endarterectomy.

Authors:  Gaurav Sharma; Ming Tao; Kui Ding; David Yu; William King; Galina Deyneko; Xiaosong Wang; Alban Longchamp; Frederick J Schoen; C Keith Ozaki; Marcus E Semel
Journal:  Stroke       Date:  2015-05-12       Impact factor: 7.914

6.  Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients.

Authors:  Gholam Basati; Morteza Pourfarzam; Ahmad Movahedian; Saed Ziaaldin Samsamshariat; Nizal Sarrafzadegan
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).

Authors:  Naoto Katakami; Tomoya Mita; Yoko Irie; Mitsuyoshi Takahara; Taka-Aki Matsuoka; Masahiko Gosho; Hirotaka Watada; Iichiro Shimomura
Journal:  Cardiovasc Diabetol       Date:  2018-02-05       Impact factor: 9.951

8.  Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study.

Authors:  Naofumi Yoshida; Hiroyuki Yamamoto; Toshiro Shinke; Hiromasa Otake; Masaru Kuroda; Daisuke Terashita; Hachidai Takahashi; Kazuhiko Sakaguchi; Yushi Hirota; Takuo Emoto; Hilman Zulkifli Amin; Taiji Mizoguchi; Tomohiro Hayashi; Naoto Sasaki; Tomoya Yamashita; Wataru Ogawa; Ken-Ichi Hirata
Journal:  Cardiovasc Diabetol       Date:  2017-08-08       Impact factor: 9.951

9.  Cystatin C-Adiponectin Complex in Plasma Associates with Coronary Plaque Instability.

Authors:  Akane Matsumoto; Hiroyasu Yamamoto; Tetsuro Matsuoka; Kento Kayama; Sumire Onishi; Natsumi Matsuo; Shinji Kihara
Journal:  J Atheroscler Thromb       Date:  2017-03-17       Impact factor: 4.928

10.  Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome.

Authors:  Bárbara Campos Abreu Marino; Nermina Buljubasic; Martijn Akkerhuis; Jin M Cheng; Hector M Garcia-Garcia; Evelyn Regar; Robert-Jan van Geuns; Patrick W Serruys; Eric Boersma; Isabella Kardys
Journal:  Arq Bras Cardiol       Date:  2018-09       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.